Rheumatologists Report Widespread Adoption and Anticipated Gains for Celgene’s Otezla in Psoriatic Arthritis
TNF share expected to erode as Otezla sees greater adoption, according to Spherix Global Insights, GmbH September 8, 2015 – Zug, Switzerland – Feedback gathered from 101 US rheumatologists during late July and early August reveals a major shift in PsA treatment focused on the uptake and expanded use of Otezla. According to the latest […]
Rheumatologists Plan to Increase their Use of Pfizer’s Xeljanz, Janssen’s Simponi and Roche’s Actemra in the Next Month
Over 40% of current Xeljanz users expect to increase use, with many rheumatologists initiating the agent prior to biologics, according to Spherix Global Insights, GmbH September 1, 2015 – Zug, Switzerland – Feedback gathered from 101 rheumatologists in August reveals that while anti-TNF inhibitors remain entrenched in most practices, use of Xeljanz, Actemra and Simponi […]
Nephrologists Perceive the Anemia Effects of Keryx’s Auryxia to be Favorable, but Market Penetration at Six Months Post Launch is Low
Download Familiarity with Auryxia is the primary barrier to adoption and growth, according to Spherix Global Insights, GmbH August 20, 2015 – Zug, Switzerland –RealTime Dynamix: Nephrology reveals that while Keryx contact rates for Auryxia are in line with those of competitors, familiarity with the product remains low. Market access also appears to be a […]
